Stay informed with our free disruptive technology investing newsletter, Nanalyze Weekly. Signup now at https://www.nanalyze.com/nanalyze-weekly/. This episode is pulled from a YouTube presentation. View the original presentation at https://youtu.be/g7m-Gs9_UB8.

AbCellera stock hasn't been treating investors well at any time frame as ABCL stock hits 52-week lows. While AbCellera has plenty of cash and runway, we're more concerned with how quickly they're progressing molecules into the clinic. Now that Eli Lilly's revenues have dried up, we can now have a better picture of the company's financial picture with the one-off aside. In looking AbCellera's clinical pipeline, we're curious why a good chunk of it relates to their mouse platform as opposed to the AI-powered drug discovery platform. To summarize, our AbCellera stock analysis points to a company that's not progressing fast enough if they hope to have more than one drug molecule achieving commercialization in the coming years.

Ver todos los episodios